ArticleKidney international reports2026
Empagliflozin and Ultrafiltration Volume in Patients Undergoing Peritoneal Dialysis.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study.Clinical kidney journal · 2026Article
- SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art.Clinical kidney journal · 2026Review
- Dapagliflozin May Increase Ultrafiltration and Urine Volume in Nondiabetic Peritoneal Dialysis Patients: A Case Series Report.Case reports in nephrology and dialysisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sodium-glucose cotransporter 2 (SGLT2) is expressed in the human peritoneum, and preclinical studies suggest that SGLT2 inhibitors may enhance ultrafiltration by reducing glucose absorption from peritoneal dialysis (PD) solutions. This study evaluated whether empagliflozin increases ultrafiltration volume (UFV) in patients on PD. Methods: In this multicenter, randomized (1:1), double-blind, placebo-controlled crossover trial, patients on PD received empagliflozin (10 mg/d) or placebo for 8 weeks, separated by a 4-week washout period. The primary outcome was the change in daily UFV from baseline to week 8 in each treatment period. Results: Of 40 randomized patients, 37 received treatment and were analyzed. The median age was 66 years, PD duration was 2.8 years, and 46% were female. At baseline, median daily UFV was 476 ml with 4500 ml of glucose-based dialysate. At week 8, change in UFV did not significantly differ between treatments (-38 ml; 95% confidence interval [CI]: -120 to 44; Conclusion: Empagliflozin did not significantly improve UFV in patients on PD, suggesting limited short-term clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.